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Abstract
Retrovirology provides the opportunity for readers to post comments online for all published
articles. These comments are moderated by the journal editors and are often peer reviewed prior
to posting. Retrovirology welcomes comments, but asks that they be written civilly.
Retrovirology is an Open Access journal. Every Retrovirology
article is immediately available upon publication for all to
read online, fee-free, in full text [1,2]. An Open Access
journal is different from a subscription journal because
the latter requires readers to pay a fee in order to access the
full text content. On April 7th, 2008, the United States
National Institutes of Health (NIH) nudged journal pub-
lishing a step closer towards universal Open Access. Begin-
ning on that day, NIH stipulated that all manuscripts
accepted for publication from NIH funded research must
be deposited in full text into PubMed Central (PMC), an
NIH online digital repository. Such articles in PMC will
become freely accessible for all to read without charge no
later than 12 months after publication.
The NIH move is timely, and it parallels a growing trend
that "fee-free" online access has become the public's
choice for securing knowledge. For example, the Wall
Street Journal reported on April 18, 2008, that print/sub-
scription revenue at a major American newspaper, the
New York Times (NYT), declined by 12.5% in March 2008
compared to March 2007. Interestingly, in the same
report, fee-free access to the NYT's online news site was
shown to have increased steadily and robustly.
Retrovirology's 5-year experience echoes the above find-
ings. It is not unusual that a published Retrovirology article
is accessed one thousand or more times within the first
week of its online appearance. In fact, during 2007, the
two most highly accessed Retrovirology papers were each
read more than 5,000 times [3]; [4]. Although we do not
have firm data, elsewhere it has been shown that Open
Access articles are more widely read and more highly cited
than their non-Open Access counterparts [5].
Open Access publishing appears to clearly benefit authors.
Interestingly, the current technology of online publishing
holds similar promise for interactive and nearly instanta-
neous participation from readers. Unlike printed journals
which cannot allow readers to quickly share their
thoughts with others, Retrovirology's "comment" tool is a
facile digital means for a reader to post his/her immediate
impressions of/reactions to a published piece. A feature of
Open Access is that the possible range of contributors to
the comment forum becomes vastly greater than those
who are permitted at a subscription site (e.g. commenta-
tors could include journalists, students, retired research-
ers, or anyone in the interested public).
A posted "comment" at Retrovirology is always moderated
by an editor and is frequently peer-reviewed. It is a tad dis-
appointing that most readers are reticent about posting
"comments" at Retrovirology, and a similar reluctance is
seen at other journals. Nevertheless, on occasion, lengthy
postings appear and are followed quickly by thoughtful
rejoinders from authors [6]. These lively but considered
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exchanges inform the discussion and enrich the dissemi-
nation and interpretation of scientific results.
Some comments proffered by readers are declined by Ret-
rovirology. Without going to great lengths into individual
reasons for each case, these unposted comments usually
suffer from one or more of the following deficiencies: they
are belittling of colleagues; they contain personal asper-
sions; they are oblivious to balanced views on an issue; or
they lack civility. Why does civility matter? It matters
because civility respects the vulnerabilities of participants,
and it elevates the dialogue to focus on the content being
communicated rather than the process or the inferred
motives of information exchange. At Retrovirology, we wel-
come and encourage your comments, but we urge you to
be civil.
Two final thoughts on posting comments – wait 24 hours
and allow your emotion to cool before writing your mis-
sive; and by all means disagree, but please don't be disa-
greeable!
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